市場調査レポート
商品コード
1193134

月経困難症治療市場:タイプ別、治療法別、流通チャネル別:世界の機会分析および産業予測、2021-2031年

Menstrual Cramps Treatment Market By Type, By Treatment, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: | 発行: Allied Market Research | ページ情報: 英文 207 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.55円
月経困難症治療市場:タイプ別、治療法別、流通チャネル別:世界の機会分析および産業予測、2021-2031年
出版日: 2022年10月01日
発行: Allied Market Research
ページ情報: 英文 207 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

月経困難症は下腹部の強いけいれん性の痛みです。

多くの女性が生理の直前から生理中にかけて月経困難症を経験します。子宮内膜症や子宮筋腫などの疾患が原因となることもあります。月経困難症の症状としては、下腹部がズキズキと痛んだり、腰や太ももが痛んだりすることがあります。また、吐き気や便の緩み、頭痛、めまいなどを経験する女性もいます。

世界の月経困難症治療市場の成長は、女性の月経困難症の増加に伴う月経困難症治療に対する需要の増加が主な要因となっています。また、月経困難症治療に対する認知度の向上が、月経困難症治療市場の成長をさらに後押ししています。しかし、月経困難症治療に関する知識の不足や、吐き気、便秘、嘔吐などの月経困難症治療薬の副作用が市場の成長を妨げています。一方、新興市場の成長機会や世界の支出増は、市場参加者に有利な機会を提供すると予想されます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資ポケット
  • ポーターのファイブフォース分析
  • 主要企業のポジショニング
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • COVID-19 影響分析

第4章 月経困難症治療市場:タイプ別

  • 概要
    • 市場規模および予測
  • 原発性月経困難症
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • 二次性月経困難症
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別

第5章 月経困難症治療市場:治療別

  • 概要
    • 市場規模および予測
  • 非ステロイド性抗炎症薬
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • ホルモン療法
    • 主要な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別

第6章 月経困難症治療市場:流通チャネル別

  • 概要
    • 市場規模・予測
  • 病院薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • ドラッグストア、小売薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • オンラインプロバイダー
    • 主要な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別

第7章 月経困難症治療市場:地域別

  • 概要
    • 市場規模・予測
  • 北米
    • 主要動向と機会
    • 北米市場規模・予測:タイプ別
    • 北米市場規模・予測:治療法別
    • 北米市場規模・予測:流通チャネル別
    • 北米市場規模・予測:国別
      • 米国
      • カナダ
      • メキシコ
  • 欧州
    • 主な動向と機会
    • 欧州の市場規模・予測:タイプ別
    • 欧州市場規模・予測:治療法別
    • 欧州市場規模・予測:流通チャネル別
    • 欧州市場規模・予測:国別
      • ドイツ
      • フランス
      • 英国
      • イタリア
      • スペイン
      • その他の欧州地域
  • アジア太平洋地域
    • 主な動向と機会
    • アジア太平洋地域の市場規模・予測:タイプ別
    • アジア太平洋地域の市場規模・予測:治療法別
    • アジア太平洋地域の市場規模・予測:流通チャネル別
    • アジア太平洋地域の市場規模・予測:国別
      • 日本
      • 中国
      • インド
      • オーストラリア
      • 韓国
      • その他アジア太平洋地域
  • LAMEA
    • 主な動向と機会
    • LAMEAの市場規模・予測:タイプ別
    • LAMEAの市場規模・予測:治療法別
    • LAMEAの市場規模・予測:流通チャネル別
    • LAMEAの市場規模・予測:国別
      • ブラジル
      • サウジアラビア
      • 南アフリカ共和国
      • LAMEAの残りの地域

第8章 企業情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合のヒートマップ
  • 主な発展

第9章 企業プロファイル

  • AbbVie Inc.
  • Bayer AG
  • Johnson and Johnson
  • Taj Pharmaceuticals Limited
  • Torrent Pharmaceuticals Ltd.
  • Abbott Laboratories
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
図表

LIST OF TABLES

  • TABLE 1. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 2. MENSTRUAL CRAMPS TREATMENT MARKET FOR PRIMARY DYSMENORRHEA, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 3. MENSTRUAL CRAMPS TREATMENT MARKET FOR PRIMARY DYSMENORRHEA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 4. MENSTRUAL CRAMPS TREATMENT MARKET FOR SECONDARY DYSMENORRHEA, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 5. MENSTRUAL CRAMPS TREATMENT MARKET FOR SECONDARY DYSMENORRHEA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 6. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 7. MENSTRUAL CRAMPS TREATMENT MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 8. MENSTRUAL CRAMPS TREATMENT MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 9. MENSTRUAL CRAMPS TREATMENT MARKET FOR HORMONAL THERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. MENSTRUAL CRAMPS TREATMENT MARKET FOR HORMONAL THERAPY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. MENSTRUAL CRAMPS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. MENSTRUAL CRAMPS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. MENSTRUAL CRAMPS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. MENSTRUAL CRAMPS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. MENSTRUAL CRAMPS TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. MENSTRUAL CRAMPS TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. GERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. GERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. GERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. UK MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. UK MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. UK MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. REST OF EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. REST OF EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. REST OF EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. ASIA-PACIFIC MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. ASIA-PACIFIC MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. ASIA-PACIFIC MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. ASIA-PACIFIC MENSTRUAL CRAMPS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. JAPAN MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. JAPAN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. JAPAN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. CHINA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. CHINA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. CHINA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. INDIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. INDIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. INDIA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. AUSTRALIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. AUSTRALIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. AUSTRALIA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. SOUTH KOREA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. SOUTH KOREA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. SOUTH KOREA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. REST OF ASIA-PACIFIC MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. REST OF ASIA-PACIFIC MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. REST OF ASIA-PACIFIC MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. LAMEA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. LAMEA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. LAMEA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. LAMEA MENSTRUAL CRAMPS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. BRAZIL MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. BRAZIL MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. BRAZIL MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 88. SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 89. REST OF LAMEA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 90. REST OF LAMEA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 91. REST OF LAMEA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 92.ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 93.ABBVIE INC.: OPERATING SEGMENTS
  • TABLE 94.ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 95.ABBVIE INC.: NET SALES
  • TABLE 96.ABBVIE INC.: KEY STRATERGIES
  • TABLE 97.BAYER AG: COMPANY SNAPSHOT
  • TABLE 98.BAYER AG: OPERATING SEGMENTS
  • TABLE 99.BAYER AG: PRODUCT PORTFOLIO
  • TABLE 100.BAYER AG: NET SALES
  • TABLE 101.BAYER AG: KEY STRATERGIES
  • TABLE 102.JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 103.JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 104.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 105.JOHNSON AND JOHNSON: NET SALES
  • TABLE 106.JOHNSON AND JOHNSON: KEY STRATERGIES
  • TABLE 107.TAJ PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
  • TABLE 108.TAJ PHARMACEUTICALS LIMITED: OPERATING SEGMENTS
  • TABLE 109.TAJ PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
  • TABLE 110.TAJ PHARMACEUTICALS LIMITED: NET SALES
  • TABLE 111.TAJ PHARMACEUTICALS LIMITED: KEY STRATERGIES
  • TABLE 112.TORRENT PHARMACEUTICALS LTD.: COMPANY SNAPSHOT
  • TABLE 113.TORRENT PHARMACEUTICALS LTD.: OPERATING SEGMENTS
  • TABLE 114.TORRENT PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
  • TABLE 115.TORRENT PHARMACEUTICALS LTD.: NET SALES
  • TABLE 116.TORRENT PHARMACEUTICALS LTD.: KEY STRATERGIES
  • TABLE 117.ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 118.ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 119.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 120.ABBOTT LABORATORIES: NET SALES
  • TABLE 121.ABBOTT LABORATORIES: KEY STRATERGIES
  • TABLE 122.DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 123.DR. REDDY'S LABORATORIES LTD.: OPERATING SEGMENTS
  • TABLE 124.DR. REDDY'S LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 125.DR. REDDY'S LABORATORIES LTD.: NET SALES
  • TABLE 126.DR. REDDY'S LABORATORIES LTD.: KEY STRATERGIES
  • TABLE 127.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 128.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 129.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 130.GLAXOSMITHKLINE PLC: NET SALES
  • TABLE 131.GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 132.PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 133.PFIZER INC.: OPERATING SEGMENTS
  • TABLE 134.PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 135.PFIZER INC.: NET SALES
  • TABLE 136.PFIZER INC.: KEY STRATERGIES
  • TABLE 137.SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 138.SUN PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 139.SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 140.SUN PHARMACEUTICAL INDUSTRIES LTD.: NET SALES
  • TABLE 141.SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.MENSTRUAL CRAMPS TREATMENT MARKET SEGMENTATION
  • FIGURE 2.MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031
  • FIGURE 3.MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.MENSTRUAL CRAMPS TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.MENSTRUAL CRAMPS TREATMENT MARKET,BY TYPE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF PRIMARY DYSMENORRHEA MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF SECONDARY DYSMENORRHEA MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031(%)
  • FIGURE 15.MENSTRUAL CRAMPS TREATMENT MARKET,BY TREATMENT,2021(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF HORMONAL THERAPY MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031(%)
  • FIGURE 18.MENSTRUAL CRAMPS TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031(%)
  • FIGURE 22.MENSTRUAL CRAMPS TREATMENT MARKET BY REGION,2021
  • FIGURE 23.U.S. MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 24.CANADA MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 25.MEXICO MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 26.GERMANY MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 27.FRANCE MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 28.UK MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 29.ITALY MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 30.SPAIN MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 31.REST OF EUROPE MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 32.JAPAN MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 33.CHINA MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 34.INDIA MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 35.AUSTRALIA MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 36.SOUTH KOREA MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 37.REST OF ASIA-PACIFIC MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 38.BRAZIL MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 39.SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 40.SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 41.REST OF LAMEA MENSTRUAL CRAMPS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46.COMPETITIVE DASHBOARD
  • FIGURE 47.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 48.ABBVIE INC..: NET SALES ($MILLION)
  • FIGURE 49.BAYER AG.: NET SALES ($MILLION)
  • FIGURE 50.JOHNSON AND JOHNSON.: NET SALES ($MILLION)
  • FIGURE 51.TAJ PHARMACEUTICALS LIMITED.: NET SALES ($MILLION)
  • FIGURE 52.TORRENT PHARMACEUTICALS LTD..: NET SALES ($MILLION)
  • FIGURE 53.ABBOTT LABORATORIES.: NET SALES ($MILLION)
  • FIGURE 54.DR. REDDY'S LABORATORIES LTD..: NET SALES ($MILLION)
  • FIGURE 55.GLAXOSMITHKLINE PLC.: NET SALES ($MILLION)
  • FIGURE 56.PFIZER INC..: NET SALES ($MILLION)
  • FIGURE 57.SUN PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ($MILLION)
目次
Product Code: A15451

Menstrual cramps are strong cramping pains in lower abdomen. Many women experience menstrual pains shortly before and throughout their periods. It can be caused by conditions such as endometriosis or uterine fibroids. Symptoms of menstrual cramps include throbbing or cramping pain in the lower abdomen, and pain in lower back and thighs. Some women also experience nausea, loose stools, headache, and dizziness.

The growth of global menstrual cramps treatment market is majorly driven by increase in demand for menstrual cramps treatment, owing to rise in cases of menstrual pain in women. In addition, growing awareness of menstrual cramps treatment further drive growth of the menstrual cramps treatment market. However, lack of knowledge regarding menstrual cramps treatment and side effects of menstrual cramps drugs such as nausea, constipation and vomiting hinders the market growth. Conversely, growth opportunities in emerging markets and surge in expenditure worldwide are anticipated to provide lucrative opportunities to the market players.

The menstrual cramps treatment market is segmented into type, treatment, distribution channel, and region. On the basis of type, the market is categorized into primary dysmenorrhea and secondary dysmenorrhea. On the basis of treatment, the market is segregated into non-steroidal anti-inflammatory drugs and hormonal therapy. On the basis of distribution channel, the market is classified into hospital pharmacies and drug stores & retail pharmacies and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major Key players that operate in the global menstrual cramps treatment market are Abbott Laboratories, AbbVie Inc., Bayer AG, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson Private Limited, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Limited, and Torrent Pharmaceuticals.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the menstrual cramps treatment market analysis from 2021 to 2031 to identify the prevailing menstrual cramps treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the menstrual cramps treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global menstrual cramps treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Primary Dysmenorrhea
  • Secondary Dysmenorrhea

By Treatment

  • Non-steroidal Anti-inflammatory Drugs
  • Hormonal Therapy

By Distribution Channel

  • Hospital Pharmacies
  • Drug stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • AbbVie Inc.
    • Bayer AG
    • Johnson and Johnson
    • Taj Pharmaceuticals Limited
    • Torrent Pharmaceuticals Ltd.
    • Abbott Laboratories
    • Dr. Reddy's Laboratories Ltd.
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Sun Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Primary Dysmenorrhea
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Secondary Dysmenorrhea
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country

CHAPTER 5: MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Non-steroidal Anti-inflammatory Drugs
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Hormonal Therapy
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country

CHAPTER 6: MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospital Pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market share analysis by country
  • 6.3 Drug stores and Retail Pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market share analysis by country
  • 6.4 Online Providers
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market share analysis by country

CHAPTER 7: MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Type
    • 7.2.3 North America Market size and forecast, by Treatment
    • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Key market trends, growth factors and opportunities
      • 7.2.5.1.2 Market size and forecast, by Type
      • 7.2.5.1.3 Market size and forecast, by Treatment
      • 7.2.5.1.4 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Key market trends, growth factors and opportunities
      • 7.2.5.2.2 Market size and forecast, by Type
      • 7.2.5.2.3 Market size and forecast, by Treatment
      • 7.2.5.2.4 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Key market trends, growth factors and opportunities
      • 7.2.5.3.2 Market size and forecast, by Type
      • 7.2.5.3.3 Market size and forecast, by Treatment
      • 7.2.5.3.4 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Type
    • 7.3.3 Europe Market size and forecast, by Treatment
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Key market trends, growth factors and opportunities
      • 7.3.5.1.2 Market size and forecast, by Type
      • 7.3.5.1.3 Market size and forecast, by Treatment
      • 7.3.5.1.4 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Key market trends, growth factors and opportunities
      • 7.3.5.2.2 Market size and forecast, by Type
      • 7.3.5.2.3 Market size and forecast, by Treatment
      • 7.3.5.2.4 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Key market trends, growth factors and opportunities
      • 7.3.5.3.2 Market size and forecast, by Type
      • 7.3.5.3.3 Market size and forecast, by Treatment
      • 7.3.5.3.4 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Key market trends, growth factors and opportunities
      • 7.3.5.4.2 Market size and forecast, by Type
      • 7.3.5.4.3 Market size and forecast, by Treatment
      • 7.3.5.4.4 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Key market trends, growth factors and opportunities
      • 7.3.5.5.2 Market size and forecast, by Type
      • 7.3.5.5.3 Market size and forecast, by Treatment
      • 7.3.5.5.4 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Key market trends, growth factors and opportunities
      • 7.3.5.6.2 Market size and forecast, by Type
      • 7.3.5.6.3 Market size and forecast, by Treatment
      • 7.3.5.6.4 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Treatment
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Key market trends, growth factors and opportunities
      • 7.4.5.1.2 Market size and forecast, by Type
      • 7.4.5.1.3 Market size and forecast, by Treatment
      • 7.4.5.1.4 Market size and forecast, by Distribution Channel
      • 7.4.5.2 China
      • 7.4.5.2.1 Key market trends, growth factors and opportunities
      • 7.4.5.2.2 Market size and forecast, by Type
      • 7.4.5.2.3 Market size and forecast, by Treatment
      • 7.4.5.2.4 Market size and forecast, by Distribution Channel
      • 7.4.5.3 India
      • 7.4.5.3.1 Key market trends, growth factors and opportunities
      • 7.4.5.3.2 Market size and forecast, by Type
      • 7.4.5.3.3 Market size and forecast, by Treatment
      • 7.4.5.3.4 Market size and forecast, by Distribution Channel
      • 7.4.5.4 Australia
      • 7.4.5.4.1 Key market trends, growth factors and opportunities
      • 7.4.5.4.2 Market size and forecast, by Type
      • 7.4.5.4.3 Market size and forecast, by Treatment
      • 7.4.5.4.4 Market size and forecast, by Distribution Channel
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Key market trends, growth factors and opportunities
      • 7.4.5.5.2 Market size and forecast, by Type
      • 7.4.5.5.3 Market size and forecast, by Treatment
      • 7.4.5.5.4 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Key market trends, growth factors and opportunities
      • 7.4.5.6.2 Market size and forecast, by Type
      • 7.4.5.6.3 Market size and forecast, by Treatment
      • 7.4.5.6.4 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Type
    • 7.5.3 LAMEA Market size and forecast, by Treatment
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Key market trends, growth factors and opportunities
      • 7.5.5.1.2 Market size and forecast, by Type
      • 7.5.5.1.3 Market size and forecast, by Treatment
      • 7.5.5.1.4 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Key market trends, growth factors and opportunities
      • 7.5.5.2.2 Market size and forecast, by Type
      • 7.5.5.2.3 Market size and forecast, by Treatment
      • 7.5.5.2.4 Market size and forecast, by Distribution Channel
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Key market trends, growth factors and opportunities
      • 7.5.5.3.2 Market size and forecast, by Type
      • 7.5.5.3.3 Market size and forecast, by Treatment
      • 7.5.5.3.4 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Key market trends, growth factors and opportunities
      • 7.5.5.4.2 Market size and forecast, by Type
      • 7.5.5.4.3 Market size and forecast, by Treatment
      • 7.5.5.4.4 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 AbbVie Inc.
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Bayer AG
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Johnson and Johnson
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Taj Pharmaceuticals Limited
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Torrent Pharmaceuticals Ltd.
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Abbott Laboratories
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Dr. Reddy's Laboratories Ltd.
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 GlaxoSmithKline plc
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Pfizer Inc.
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Sun Pharmaceutical Industries Ltd.
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments